Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.33 |
| ▸ | CDK2 | P24941 | 6/20 | 0.33 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4B | O94953 | 1/20 | 0.31 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | PNP | P00491 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17485430 | 0.85 | KDM4A (0.43) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL17483530 | 0.82 | CDK1 (0.32) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL17485503 | 0.81 | CDK1 (0.32) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL15354460 | 0.81 | KDM4A (0.36) | KDM4AKDM4BKDM5CKDM5BPNP | |
| SCHEMBL17483528 | 0.80 | KDM4A (0.31) | CDK1CCNB1CDK2KDM4AKDM4B | |
| SCHEMBL12844134 | 0.77 | HEXA (0.37) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL6950562 | 0.77 | CDK1 (0.42) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL17483529 | 0.75 | CDK1 (0.32) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL1675432 | 0.70 | NOS1 (0.39) | CDK1CCNB1CCNA2CDK2CCNA1 | |
| SCHEMBL12775188 | 0.70 | CDK2 (0.37) | CDK1CCNB1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522146-B2 | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof | INTELLIKINE LLC (US) | 2016-12-20 | — | — | US | disclosed |
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE LLC | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031886-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | PIK3CA, PIK3CG, PIK3CB | CDK1 221/4885CCNB1 1882/4885CCNA2 1291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.